Trials / Terminated
TerminatedNCT00237536
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
A Randomized, Double-Blind, Placebo-Controlled, Dose Comparison Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (planned)
- Sponsor
- Threshold Pharmaceuticals · Industry
- Sex
- Male
- Age
- 65 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lonidamine |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-08-01
- Completion
- 2006-08-01
- First posted
- 2005-10-12
- Last updated
- 2009-04-29
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00237536. Inclusion in this directory is not an endorsement.